Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gore, S.M.
Right arrow Articles by Goldberg, D.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gore, S.M.
Right arrow Articles by Goldberg, D.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 1999; 92: 25-32
© 1999 Association of Physicians

Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours

S.M. Gore, A.G. Bird1, S.O. Cameron2, S.J. Hutchinson3, S.M. Burns4 and D.J. Goldberg5

From the MRC Biostatistics Unit, Cambridge, 1 Department of Immunology, John Radcliffe Hospital, Oxford, 2 Regional Virus Laboratory, Glasgow, 3 MRC-BIAS, Edinburgh, 4 Regional Virus Laboratory, Edinburgh and 5 Scottish Centre for Infection and Environmental Health, Glasgow, UK

Received 11 September 1998 and in revised form 9 November 1998

We used cross-sectional willing anonymous salivary hepatitis C (WASH-C) surveillance linked to self-completed risk-factor questionnaires to estimate the prevalence of salivary hepatitis C antibodies (HepCAbS) in five Scottish prisons from 1994 to 1996. Of 2121 available inmates, 1864 (88%) participated and 1532/1864 (82%) stored samples were suitable for testing. Overall 311/1532 (20.3%, prevalence 95%CI 18.3–22.3%) were HepCAbS-positive: 265/536 (49%, 95%CI 45–54%) injector-inmates but only 27/899 (3%, 95%CI 2–4%) non-injector-inmates. Among injectors, HepCAbS positivity was only slightly higher (p=0.03) in those who had injected inside prison (53%, 162/305) than in those who had not (44%, 98/224). Those who began injecting in 1992–96 were much less likely to be HepCAbS-positive than those who started pre-1992 (31%, 35/114 vs. 55%, 230/422; p<0.001). Even with injectors who began in 1992–96 but had never injected inside prison, the prevalence of hepatitis C carriage was 17/63 (95%CI 16–38%). The prevalence and potential transmissibility of hepatitis C in injector-inmates are both high. Promoting `off injecting' before `off drugs' (both inside and outside prison), methadone prescription during short incarcerations, alternatives to prison, and support of HepCAbS-positive inmates in becoming eligible for treatment, all warrant urgent consideration.

Address correspondence to Dr S.M. Gore, MRC Biostatistics Unit, Institute of Public Health, Robinson Way, Cambridge CB2 2SR


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
R. Chou, E. C. Clark, and M. Helfand
Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, March 16, 2004; 140(6): 465 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. K. Champion, A. Taylor, S. Hutchinson, S. Cameron, J. McMenamin, A. Mitchell, and D. Goldberg
Incidence of Hepatitis C Virus Infection and Associated Risk Factors among Scottish Prison Inmates: A Cohort Study
Am. J. Epidemiol., March 1, 2004; 159(5): 514 - 519.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J. Long, S. Allwright, J. Barry, S. R. Reynolds, L. Thornton, F. Bradley, J. V Parry, and S. M Bird
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey Commentary: efficient research gives direction on prisoners' and the wider public health---except in England and Wales
BMJ, November 24, 2001; 323(7323): 1209 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 Criminal JusticeHome page
K. DUKE
Evidence-Based Policy Making?: The Interplay between Research and the Development of Prison Drugs Policy
JCriminology and Criminal Justice, August 1, 2001; 1(3): 277 - 300.
[Abstract] [PDF]

Home page
 QJMHome page
S.L. Jowett, K. Agarwal, B.C. Smith, W. Craig, M. Hewett, D.R. Bassendine, E. Gilvarry, A.D. Burt, and M.F. Bassendine
Managing chronic hepatitis C acquired through intravenous drug use
QJM, March 1, 2001; 94(3): 153 - 158.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. Allwright, F. Bradley, J. Long, J. Barry, L. Thornton, and J. V Parry
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey
BMJ, July 8, 2000; 321(7253): 78 - 82.
[Abstract] [Full Text]

Home page
 QJMHome page
P.M. Ford, M. Pearson, P. Sankar-Mistry, T. Stevenson, D. Bell, and J. Austin
HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary
QJM, February 1, 2000; 93(2): 113 - 119.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.